by dyadic | Jul 29, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and...
by dyadic | Jul 27, 2021 | Press Releases
Potential for Affordable COVID-19 Immunization Coverage in Underserved African CountriesArrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through...
by dyadic | Jun 28, 2021 | Press Releases
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1...
by dyadic | May 26, 2021 | Press Releases
In collaboration with Syngene International Ltd.JUPITER, Fla., May 26, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying...
by dyadic | May 24, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production...
by dyadic | May 13, 2021 | Press Releases
Advancing Dyadic’s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development...
